Bruker (NASDAQ:BRKR) Downgraded by Wall Street Zen to Hold

Bruker logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen downgraded Bruker from “Buy” to “Hold.” The broader analyst consensus is also “Hold,” with an average price target of $61.
  • Bruker reported quarterly earnings of $0.56 per share, beating the $0.42 estimate, while revenue of $874 million exceeded forecasts and rose 1.6% year over year.
  • Analyst views remain mixed: one Strong Buy, five Buys, seven Holds, and one Sell, with price targets ranging from $60 to $72 among the firms cited.
  • Interested in Bruker? Here are five stocks we like better.

Bruker (NASDAQ:BRKR - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a note issued to investors on Saturday, Wall Street Zen reports.

A number of other brokerages have also weighed in on BRKR. UBS Group began coverage on shares of Bruker in a report on Wednesday, September 9th. They set a "neutral" rating and a $65.00 price objective on the stock. JPMorgan Chase & Co. lowered Bruker from an "overweight" rating to a "neutral" rating and set a $60.00 target price for the company. in a research note on Wednesday, October 14th. Guggenheim lifted their price target on Bruker from $70.00 to $72.00 and gave the stock a "buy" rating in a research report on Thursday, October 1st. The Goldman Sachs Group raised Bruker from a "strong sell" rating to a "strong-buy" rating in a research report on Monday, September 21st. Finally, Barclays boosted their price target on Bruker from $58.00 to $70.00 and gave the company an "overweight" rating in a research note on Wednesday, October 7th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $61.00.

Get Our Latest Analysis on Bruker

Bruker Stock Performance

Shares of Bruker stock opened at $56.46 on Friday. The firm has a market capitalization of $8.62 billion, a P/E ratio of -51.33, a PEG ratio of 1.76 and a beta of 1.26. The company has a quick ratio of 0.90, a current ratio of 1.84 and a debt-to-equity ratio of 0.74. The company has a 50 day moving average price of $59.99 and a 200 day moving average price of $51.31. Bruker has a 52 week low of $32.37 and a 52 week high of $68.98.

Bruker (NASDAQ:BRKR - Get Free Report) last released its earnings results on Wednesday, November 4th. The medical research company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.42 by $0.14. Bruker had a negative net margin of 3.82% and a positive return on equity of 13.76%. The company had revenue of $874.00 million for the quarter, compared to the consensus estimate of $865.16 million. During the same quarter in the previous year, the firm earned $0.45 EPS. Bruker's revenue was up 1.6% compared to the same quarter last year. Sell-side analysts expect that Bruker will post 2.13 EPS for the current year.

Insider Activity at Bruker

In other news, VP Mark Munch sold 2,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total transaction of $105,740.00. Following the sale, the vice president owned 134,806 shares of the company's stock, valued at $7,127,193.22. This trade represents a 1.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 27.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Bruker

Several large investors have recently made changes to their positions in BRKR. Wellington Management Group LLP purchased a new stake in shares of Bruker during the second quarter worth approximately $1,365,000. The Manufacturers Life Insurance Company acquired a new position in Bruker in the 2nd quarter valued at $4,536,000. Hsbc Holdings PLC purchased a new position in Bruker in the 2nd quarter valued at $5,252,000. Legal & General Group Plc purchased a new position in Bruker in the 2nd quarter valued at $8,742,000. Finally, Edmond DE Rothschild Holding S.A. purchased a new position in Bruker in the 2nd quarter valued at $169,899,000. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Company Profile

(Get Free Report)

Bruker develops and manufactures scientific instruments and analytical technologies used to study biological, chemical and physical materials. Its products support research and testing in areas including life sciences, pharmaceuticals, biotechnology, materials science, chemicals and clinical diagnostics. The company's offerings include nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray and microscopy instruments, and infrared and Raman spectroscopy solutions.

Recommended Stories

Analyst Recommendations for Bruker (NASDAQ:BRKR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Bruker Right Now?

Before you consider Bruker, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.

While Bruker currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines